HUMAN REPEAT INSULT PATCH TEST FOR SKIN IRRITATION AND SKIN SENSITIZATION EVALUATION ON 50 SUBJECTS

Study N°	CAAD1546/23-01
Study Protocol code	REL/CA3533/2023/CLI
Sponsor	Astonishing Developments Ltd. 2030 Union St Suite 206 94123 San Francisco (CA) - USA
Analyzed substance	**RevivLash Lash & Brow Stimulating Serum** **Batch: 230202A**
Date	**November 24th, 2023**

Abich Inc

5160 Décarie Boulevard
H3X 2H9 Montréal
Québec, Canada

Tel. +1 514 507 9982
Fax +1 514 507 9983
info@abich.ca

www.abich.ca | www.abich.it

Contents

1) AIM OF THE TEST 3
2) TEST MATERIAL 3
3) STUDY DATE 3
4) HANDLING 3
5) INDEPENDENT ETHICS COMMITTEE (IEC) 3
6) REGULATORY COMPLIANCE 4
7) GENERAL PRINCIPLE 4
8) PANEL FEATURES 5
9) EQUIPMENT 6
10) EXPERIMENTAL PLAN 6
11) ASSAY METHODOLOGY 8
12) SCORING 9
13) OBSERVATION 9
14) DATA ANALYSIS 10
15) RESULTS 10
16) CONCLUSION 11
17) ARCHIVING 12
18) REFERENCES 13
ANNEXES 15

1) AIM OF THE TEST

This human repeat insult patch test was conducted in order to assess the potential of the test substance to induce contact irritation or sensitization by repetitive applications to the skin of healthy volunteers.

The study was performed in the laboratory facility of Abich Inc, in 5160 Décarie Boulevard-#310 Montréal (Québec) H3X 2H9 - Canada.

2) TEST MATERIAL

Name:	**RevivLash Lash & Brow Stimulating Serum**
Batch	**230202A**
Abich sample code:	**CA1245/23-01**
Storage conditions:	Room temperature

Refer to the Annex section below for the INCI Composition

3) STUDY DATE

Start: 02/10/2023
End: 09/11/2023

4) HANDLING

Upon arrival at Abich Inc the test sample was assigned a unique laboratory code number and entered in Abich Software identifying the lot number, description, sponsor, date received and tests requested .

5) INDEPENDENT ETHICS COMMITTEE (IEC)

An independent body of medical professionals and non-medical members was constituted to ensure the protection of the rights, safety and well-being of human subjects involved in a trial and to provide public assurance of that protection. Their most important duty is reviewing, approving and providing their favorable opinion on the trial protocol, in order to ensure the suitability of the investigator(s), the facilities, the methods and material to be used in obtaining and documenting informed consent of the trial subjects.

6) REGULATORY COMPLIANCE

This study has been carried out in compliance with the most recent recommendations of the Helsinki Declaration (Helsinki Declaration 64th WMA General Assembly, Fortaleza, Brazil, October 2013) and has followed the "Guidelines for the Assessment of Skin Tolerance of Potentially Irritant Cosmetic ingredients", COLIPA, 1997.

In particular, to respect the ethical requirements imposed by the human studies, the following criteria were applied:

- Volunteers were recruited according to the recruitment criteria of inclusion and exclusion specified below (see Section 8);
- All volunteers were informed about the purpose and type of study, the possible risks, and freely gave their informed consent;
- Before the volunteers were exposed to the product, information on the toxicological profile of the product were obtained by the sponsor
- All necessary precautions have been taken to avoid excessive skin reactions or adverse effects on the health of volunteers during the study;
- Security measures have been prepared in case of adverse reactions.

7) GENERAL PRINCIPLE

The general principle of this study lies in the repeated application of 0.07 to 0.1 ml of test product to the skin of volunteers' back. The product is kept in contact with the skin under semi-occluded patch according to a predetermined schedule set to maximize the efficiency, safety, and accuracy of the human repeat insult patch test.

Changes to the concentration of the substance to be tested are implemented depending on product type and its intended use. Thus, products are either tested pure or diluted. Consequently, rinsing products are diluted at 1%, at 5% or at 10%, depending on the composition of the product. Hydrophilic products are diluted in demineralized water while lipophilic products are diluted in mineral oil. Powders are conjugated with a drop of demineralized water or mineral oil before their application to the semi-occlusive device. This enables a homogeneous dispersion and ensures sustained contact with the skin. Solid materials are reduced into small pieces of dimensions suitable to be applicable onto the test discs of the semi-occlusive device. Solid and viscous materials are applied once, while liquid materials may require multiple applications to prevent evaporation.

The assessment of skin irritation and sensitization is made by comparison with a "negative control", prepared as follows:

- If the product is tested pure: empty patch;
- If the product is tested diluted: patch with about 0.07-0.1 ml of demineralized water or mineral oil (depending on the used solvent)

8) PANEL FEATURES

8.1 Inclusion Criteria of subject in a Study

- Individuals who are enlisted in the Abich Inc laboratory database;
- Individuals who are not under a doctor's care;
- Individuals who are healthy and do not suffer from chronic or dermatologic disorder that would affect the study in any way;
- Individuals who have agreed to the study after reading, understanding and signing the informative form, informed consent form I.C.

8.2 Exclusion Criteria of subject in a Study

Prior to the beginning of the study, the following criteria were applied:

- Individuals under the legal age of 18 years old;
- Individuals under a doctor's care;
- Individuals who are not healthy and suffer from acute, chronic or dermatologic disorder that would affect the study in any way;
- Female subjects who are pregnant or nursing;
- Individuals taking chronic or occasional medication which may affect the skin response to the product;
- Individuals with skin diseases which may interfere with the objective of the present study;
- Individuals who were diagnosed with chronic skin allergies;
- Individuals taking part in other studies simultaneously using the same test site or individuals that did not have an appropriate rest period between studies.

After the beginning of the study, the following withdrawal criteria were applied:

- Individuals who did not follow the conditions as described in the Study Information Sheet;
- Individuals who suffered any illness, an accident or developed any condition which could affect the outcome of the study;
- Individuals who no longer wished to participate in the study.

For the duration of the study the volunteers were asked not to shower before the removal of the patch and to avoid exposure to UV rays on the test site.

The volunteers were also asked to report to the staff of the Abich Inc laboratory the use of any drug, particularly-anti-inflammatory drugs, steroids and antihistamines.

8.3 Recruitment

The study was performed on 50 out of 53 healthy volunteers, male and female who have been identified from the volunteers' database of the Abich Inc laboratory. Three volunteers discontinued the study due to non-compliance of the study.

8.4 Informed Consent and Medical History Form

Before the beginning of the study, each volunteer has read and signed an informative form (informed consent form, I.C.). Each volunteer has had the opportunity to ask any kind of questions regarding the study. The aim of the test, the procedure and the possible risks related were explained. Only after signature of the informed consent was the participation in the study permitted. The originals of these informed consent forms were archived at the Abich Inc laboratory. All individuals signed a consent allowing to treat personal data according to the Canadian law.

9) EQUIPMENT

The test product was applied by means of adhesive porous strips for patch tests with the use of Finn Chambers® paper discs or similar in sufficient amount to fill one test disk (0.07-0.1 ml), before semi-occluded application to the skin of the back of each volunteer.

10) EXPERIMENTAL PLAN

10.1 Structure of the study

- Phase 1 – Induction Phase:

Three (3) consecutive weeks, 3 days per week (Monday, Wednesday and Friday).

Stage 1:
On the first application, the patch remained in place for 48 hours and subjects were instructed to not remove the patch during the designated time frame. The subject then returned to the Testing Facility and the patch was removed by a technician from Abich Inc laboratory prior to the next patch application.

Stage 2:
After the stage 1, application of a semi-occlusive patch containing the product was performed. The subjects were instructed to remove it after 24 hours and to return to the Testing Facility 48 hours after application, where a technician from Abich Inc laboratory did a skin evaluation followed by the reapplication of a new patch. This procedure was repeated for a series of eight (8) consecutive times in the same area. Whenever possible, the re-patching was done on the same site each time. In case of significant irritation (level 2 or greater), the application site was shifted.

- Phase 2 – Rest Phase:

During a 10-14 days rest period, no products were applied.

- Phase 3 – Challenge Phase:

Following a 10-14 days rest period a retest/challenge patch was applied once to a previously unpatched (virgin) test site. Test site was evaluated by trained laboratory personnel 48h and 72h after application. All subjects were instructed to contact the Testing Facility to report any delayed skin reactivity after the final patch reading. When warranted, the affected subjects are then asked to return to the Testing Facility for additional examination.

Notes:

- Volunteers are required to bathe or wash before their arrival at the laboratory;
- The patches were applied on the upper back of the volunteer on the right and left of the midline;
- For the duration of the study the volunteers were asked not to shower before the removal of the patch and to avoid exposure to UV rays on the test site;
- Security measures have been prepared in case of adverse reaction and the client will be notified;
- Clinical analysis is performed according to a scale proportional to the severity of irritation for each of the considered irritation phenomena (erythema, edema, vesicles).

The study was performed in a single blind mode.

10.2 Environmental conditions

The study was performed in standard environmental conditions for each observing / reading time specified, maintaining temperature and humidity constant.

10.3 Area to be tested

The product was applied on the upper back's skin of volunteers.

10.4 Patch test application method

The patch test application method was semi-occlusive.

10.5 Preparation of the sample

The set concentration of the tested product **RevivLash Lash & Brow Stimulating Serum Batch: 230202A** is pure. The amount of substance applied to each disc was approximately 0.07-0.1 ml.

11) ASSAY METHODOLOGY

11.1 Application method

The portion of skin designated for the patch application was cleaned with demineralized water and cellulose cotton wool tissue. Sample application on the back of the volunteers ensued.

The fine positioning of the patch depended on the presence of naevi or congenital dyschromia, which were avoided.

In parallel to the application of products to be studied, a "negative" control patch was applied (empty or containing mineral oil or demineralized water).

11.2 Patch application period

The samples remained on the volunteer's skin for 48 hours. The application area was kept dry for the whole experimental time.

11.3 Patch removal

After the scheduled application period expired, the patch was removed and the area was wiped from residues. Fifteen minutes and 24 hours after patch removal, the application area was carefully examined by a technician from Abich Inc laboratory in order to evaluate skin reactions.

In particular, the following parameters were considered: erythema, desquamation, oedema and vesicles.

Each parameter was scored with values ranging from 0 to 3 to express differences in severity of the observed reactions.

12) SCORING

Scoring scale and definition of symbols shown below are based on the scoring scheme according to the international Contact Dermatitis Research Group scoring scale.

Listed Below:

- No reaction (negative)
IR Irritant reaction of different types
? or ± Doubtful reaction
+ Light erythema (non-vesicular)
++ Edema, erythema, discrete vesicles
+++ Coalescing vesiculobullous papules

D Site discontinued
Dc Subject discontinued

All observations and comments provided by the volunteers participating in the study are taken into consideration and recorded accordingly.

Note: Clinical evaluations are performed by an investigator or designee trained in the clinical evaluation of the skin. Whenever feasible, the same individual will do the scoring of all the subjects throughout the study and will be blinded to the treatment assignments and any previous scores.

13) OBSERVATION

13.1 Adverse events/Severe adverse events

In this final report, an “adverse event” is defined as any unintended or harmful response that is observed in a volunteer who is testing a product, which may not necessarily be due to the product or treatment in question. Volunteers participating in this test may be subject to a variety of adverse events such as cracking, rash, dryness or pain if the test product is strongly irritant or if the volunteer is particularly sensitive to the product. Moreover, potential development of an allergic sensitization may occur due to the test product or its ingredients.

While on the other hand, “a serious adverse event” is defined as any unforeseen occurrence that will require the subject to be hospitalized or cause significant or permanent incapacity, which may or may not be related to the test product.

No adverse events of any kind were reported during the course of this study.

14) DATA ANALYSIS

The individual scores, observed reactions and their severity, as well as their reproducibility from one volunteer to another are taken into consideration by the Dermatologist in order to evaluate the tolerance to the test product.

The tolerance to the product was evaluated by a dermatologist – considering the scores, observed reactions, their level of intensity and reproducibility from one volunteer to another.

15) RESULTS

A total of 53 healthy volunteers were recruited for this study among which 3 subjects discontinued due to non-compliance of the study. The discontinued subjects are shown in the table in Annex 1, but will not be taken into consideration in the conclusion of this final report.

INDUCTION PHASE SUMMARY

PRODUCT	CONCENTRATION	TYPE OF APPLICATION	INDUCTION SCORE	NUMBER OF RESPONSES
RevivLash Lash & Brow Stimulating Serum Batch: 230202A	PURE	SEMI-OCCLUSIVE	?	**2**
			+	**0**
			++	**0**
			+++	**0**

CHALLENGE PHASE SUMMARY

PRODUCT	CONCENTRATION	TYPE OF APPLICATION	CHALLENGE SCORE	NUMBER OF RESPONSES
RevivLash Lash & Brow Stimulating Serum Batch: 230202A	PURE	SEMI-OCCLUSIVE	?	**0**
			+	**0**
			++	**0**
			+++	**0**

16) CONCLUSION

Under the exposure conditions of this test and on the basis of the obtained results, the test substance **RevivLash Lash & Brow Stimulating Serum Batch: 230202A** may be considered a **NON IRRITANT, a NON SENSITIZER, DERMATOLOGICALLY TESTED and HYPOALLERGENIC*** to the skin according to reference.

Supervision Dermatologist
Ari Demirjian MD,
FRCPC Professeur adjoint CUSM

Verified by signNow
20/11/2023 21:34:27 UTC
bc35596368894241b595
Ari Demirjian

Study Director
Amal Elmaoui

Verified by signNow
24/11/2023 21:05:20 UTC
8a3fbf86166a49b09fdb
Amal Elma

Clinical Research Coordinator
Isabella Sammarco

Verified by signNow
24/11/2023 20:16:58 UTC
9ac5f6f6f42247d8a3e0
Isabella Sammarco

Clinical Research Assistant Coordinator
Anaelle Treesha Ragaven

Verified by signNow
24/11/2023 20:37:40 UTC
0d676a50eee346b5929d
Anaelle Treesha Ragaven

*According to Health Canada a product labelled “hypoallergenic” can still cause reactions.
“Hypoallergenic” simply means that the product is less likely to cause allergic reactions.
There are no Federal standards or definitions that govern the use of the term "hypoallergenic."
Kindly note that it is the sponsor’s responsibility to verify, with their regulatory department or consultant, the compliance of the claims that they intend to use on the labels of their products with their enforced local regulations.

17) ARCHIVING

The study protocol, the raw data and the final report will be kept at Abich Inc laboratory: 5160, Décarie Boulevard, suite 340, Montréal (Québec) H3X 2H9 – Canada, for a minimum period of 5 years from the issue of the final report.

The control sample of the test substance and eventual specific reference material will be kept for 3 months, unless the customer provides a specific request.

The Customer, upon drafting a suitable contract, may request either the extension of the conservation of all or part of the materials for a further period or their restitution.

QA STATEMENT

The volunteers' recruitment is done according to specific internal procedures, according to GCP directive and according to Helsinki Declaration, 2013 requests. The volunteers signed the personal informal consent, they were informed about the complete study plan under development.
The collected data derived from this study is managed according to internal procedures following the GLP directive and is verified by the QA manager who checks the different parts of this study (comparison between raw data and recorded data, laboratory books and files, protocol and report) according to the quality plan of ABICH Inc laboratory (internal audits, periodical calibration status of the instruments if they are involved in the test).

QA Manager
Nina Duru

Nina Duru

Verified by signNow
24/11/2023 20:40:23 UTC
c25e795e16d64ce09363
Nina Duru

18) REFERENCES

Declaration WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
Ethical Principles for Medical Research Involving Human Subjects
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the:
29th WMA General Assembly, Tokyo, Japan, October 1975
35th WMA General Assembly, Venice, Italy, October 1983
41st WMA General Assembly, Hong Kong, September 1989
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996
52nd WMA General Assembly, Edinburgh, Scotland, October 2000
53rd WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added)
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added)
59th WMA General Assembly, Seoul, October 2008
64th WMA General Assembly, Fortaleza, Brazil, October 2013

ISO 10993-10 AMD 1:2004 (Biological evaluation of medical devices - Part 10: Tests for irritation and delayed-type hypersensitivity)

Kligman A.M., Epstei W.: "Updating the maximization test for identifying contacts allergens" Contact Dermatitis 1975:1:231-239.

Draize J.H., Woodgard G., Calvery H.O. : "Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes". J.Pharmacol. Exp. Ther. 82,377 (1944).

Magnusson B. et al. : "Routine patch testing". II Acta Dermatovenereol. 46,153, (1966).

Marzulli F.N., Maibach H.I. Antimicrobials: Experimental contact sensitization in man; J. Soc. Cosmet. Chem. 2.4,399-421, 1973

Fregert S. et al. : "Epidemiology of contact dermatitis". Trans. ST. John's Hosp. Derm. Soc. 55,17, (1969).

Pirila V. : "Chamber test versus patch test for epicutaneous testing". Contact Dermatitis I, 48, (1975).

Sherertz E., Byers V.:"Estimating Dilutions for Patch Testing Skin Care Products: A Practical Method" American Journal of Contact Dermatitis, Vol 8, No 3, 1997

Brasch J., Geier H. Henseler T.: "Evaluation of patch test results by use of the reaction index. An analysis of data recorded by the information network of departments of dermatology". Contact Dermatitis, 33:385-380, (1995).

Kligman A.M., Wooding W.M. "A method for the measurement and evaluation of irritants on human skin" J.Invest.Dermatol. 40: 78-94, 1967.

Consensus documents Number 4.
OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING
"Quality assurance and GLP" 26 Oct. 1999.
Consensus documents Number 5.

OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING
"Compliance of laboratory suppliers with GLP principles" 28 Sept. 2000.
Consensus documents Number 7.
OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING
"The application of to GLP principles to short term studies" 15 Sept. 1999.
Consensus documents Number 8.
OECD SERIES ON PRINCIPALES OF GLP AND COMPLIANCE MONITORING
"The role and responsibility of the Study Director in the GLP studies" 15 Sept. 1999.

"Biological evaluation of medical devices. Part 23: Tests for irritation." ISO 10993-23. First Edition 2021-01.

Dermatoxicology Methods. Marzulli F., Maibach H. Published Taylor & Francis 1 Fifth Edition 1997

ANNEXES

ANNEX 1 – Panel of volunteers

#	CODE	Gender	Age
1	ADRA3262	F	40
2	ALGO3267	M	31
3	ALNO1687	F	25
4	ANBU1511	F	37
5	*ANDI3212	F	31
6	ANGO3254	F	34
7	ANZA2681	F	38
8	BALO2963	M	34
9	CACA3288	F	51
10	CEQU3296	F	33
11	CLPE3273	F	33
12	CRTE2954	M	27
13	DABA3246	F	31
14	DECA2827	F	39
15	DEMU3244	F	43
16	DICO0434	F	48
17	DIRA3272	F	58
18	EDMA0071	F	43
19	EDQU3252	M	47
20	ELRU2945	F	48
21	GAMI3343	F	45
22	GASO3266	F	30
23	JODU1309	F	48
24	JOFA3241	F	43
25	*KAMU3214	F	33
26	LERA3235	F	38
27	LUAB1473	F	51
28	LULA2873	F	59
29	MACA2684	F	59
30	MAOS2687	F	28
31	MAPI3257	F	41
32	*MARO3197	F	19
33	MASE1804	F	24
34	MAZA3008	F	30
35	MICL2944	F	30
36	MOAB2550	M	28

ANNEX 1 – Panel of volunteers (*continued*)

#	CODE	Gender	Age
37	MOSA3081	F	51
38	NAAN2076	F	33
39	NAIL2642	F	56
40	OUEL3268	F	19
41	RAMA3259	F	37
42	RODO1852	F	47
43	RORO3238	F	32
44	SAJA3115	F	43
45	TADE3031	F	60
46	VAAC3302	F	25
47	VILA2614	F	40
48	WACH2180	F	43
49	YERA3195	F	33
50	YERU3250	F	32
51	YHLE3236	M	40
52	YUGU3237	F	36
53	ZUDO3342	F	31
AVERAGE		**47F/6M**	**38.4**

**discontinued the study for due to non-compliance.*

ANNEX 2 – Individual Scores: RevivLash Lash & Brow Stimulating Serum Batch: 230202A

2.1 Induction Phase and Challenge Phase Individual Scores

VOLUNTEERS		INDUCTION									CHALLENGE	
Ref	Vol	1	2	3	4	5	6	7	8	9	48h	72h
1	ADRA3262	-	-	-	-	-	-	-	-	-	-	-
2	ALGO3267	-	-	-	-	-	-	-	-	-	-	-
3	ALNO1687	-	-	-	-	-	-	-	-	-	-	-
4	ANBU1511	-	-	-	-	-	-	-	-	-	-	-
5	ANDI3212	-	DC									
6	ANGO3254	-	-	-	-	-	-	-	-	-	-	-
7	ANZA2681	-	-	-	-	-	-	-	-	-	-	-
8	BALO2963	-	-	-	-	-	-	-	-	-	-	-
9	CACA3288	-	-	-	-	-	-	-	-	-	-	-
10	CEQU3296	-	-	-	-	-	-	-	-	-	-	-
11	CLPE3273	-	-	-	-	-	-	-	-	-	-	-
12	CRTE2954	-	-	-	-	-	-	-	-	-	-	-
13	DABA3246	-	-	-	-	-	-	-	-	-	-	-
14	DECA2827	-	-	-	-	-	-	-	-	-	-	-
15	DEMU3244	-	-	-	-	-	-	-	-	-	-	-
16	DICO0434	-	-	-	-	-	-	-	-	-	-	-
17	DIRA3272	-	-	-	-	-	-	-	-	-	-	-
18	EDMA0071	-	-	-	-	-	-	-	-	-	-	-
19	EDQU3252	-	-	-	-	-	-	-	-	-	-	-
20	ELRU2945	-	-	-	-	-	-	-	-	-	-	-
21	GAMI3343	-	-	-	-	-	-	-	-	-	-	-
22	GASO3266	-	-	-	-	-	-	-	-	-	-	-
23	JODU1309	-	-	?	-	-	-	-	-	-	-	-
24	JOFA3241	-	-	-	?	-	-	-	-	-	-	-
25	KAMU3214	-	DC									
26	LERA3235	-	-	-	-	-	-	-	-	-	-	-

ANNEX 2 – Individual Scores: RevivLash Lash & Brow Stimulating Serum Batch: 230202A (*continued*)

2.1 Induction Phase and Challenge Phase Individual Scores (*continued*)

VOLUNTEERS		INDUCTION									CHALLENGE	
Ref	Vol	1	2	3	4	5	6	7	8	9	48h	72h
27	LUAB1473	-	-	-	-	-	-	-	-	-	-	-
28	LULA2873	-	-	-	-	-	-	-	-	-	-	-
29	MACA2684	-	-	-	-	-	-	-	-	-	-	-
30	MAOS2687	-	-	-	-	-	-	-	-	-	-	-
31	MAPI3257	-	-	-	-	-	-	-	-	-	-	-
32	MARO3197	-	DC									
33	MASE1804	-	-	-	-	-	-	-	-	-	-	-
34	MAZA3008	-	-	-	-	-	-	-	-	-	-	-
35	MICL2944	-	-	-	-	-	-	-	-	-	-	-
36	MOAB2550	-	-	-	-	-	-	-	-	-	-	-
37	MOSA3081	-	-	-	-	-	-	-	-	-	-	-
38	NAAN2076	-	-	-	-	-	-	-	-	-	-	-
39	NAIL2642	-	-	-	-	-	-	-	-	-	-	-
40	OUEL3268	-	-	-	-	-	-	-	-	-	-	-
41	RAMA3259	-	-	-	-	-	-	-	-	-	-	-
42	RODO1852	-	-	-	-	-	-	-	-	-	-	-
43	RORO3238	-	-	-	-	-	-	-	-	-	-	-
44	SAJA3115	-	-	-	-	-	-	-	-	-	-	-
45	TADE3031	-	-	-	-	-	-	-	-	-	-	-
46	VAAC3302	-	-	-	-	-	-	-	-	-	-	-
47	VILA2614	-	-	-	-	-	-	-	-	-	-	-
48	WACH2180	-	-	-	-	-	-	-	-	-	-	-
49	YERA3195	-	-	-	-	-	-	-	-	-	-	-
50	YERU3250	-	-	-	-	-	-	-	-	-	-	-
51	YHLE3236	-	-	-	-	-	-	-	-	-	-	-
52	YUGU3237	-	-	-	-	-	-	-	-	-	-	-
53	ZUDO3342	-	-	-	-	-	-	-	-	-	-	-

ANNEX 3 – Individual Scores: Control

3.1 Induction Phase and Challenge Phase Individual Scores of the empty semi-occlusive patch

VOLUNTEERS		INDUCTION									CHALLENGE	
Ref	Vol	1	2	3	4	5	6	7	8	9	48h	72h
1	ADRA3262	-	-	-	-	-	-	-	-	-	-	-
2	ALGO3267	-	-	-	-	-	-	-	-	-	-	-
3	ALNO1687	-	-	-	-	-	-	-	-	-	-	-
4	ANBU1511	-	-	-	-	-	-	-	-	-	-	-
5	ANDI3212	-	DC									
6	ANGO3254	-	-	-	-	-	-	-	-	-	-	-
7	ANZA2681	-	-	-	-	-	-	-	-	-	-	-
8	BALO2963	-	-	-	-	-	-	-	-	-	-	-
9	CACA3288	-	-	-	-	-	-	-	-	-	-	-
10	CEQU3296	-	-	-	-	-	-	-	-	-	-	-
11	CLPE3273	-	-	-	-	-	-	-	-	-	-	-
12	CRTE2954	-	-	-	-	-	-	-	-	-	-	-
13	DABA3246	-	-	-	-	-	-	-	-	-	-	-
14	DECA2827	-	-	-	-	-	-	-	-	-	-	-
15	DEMU3244	-	-	-	-	-	-	-	-	-	-	-
16	DICO0434	-	-	-	-	-	-	-	-	-	-	-
17	DIRA3272	-	-	-	-	-	-	-	-	-	-	-
18	EDMA0071	-	-	-	-	-	-	-	-	-	-	-
19	EDQU3252	-	-	-	-	-	-	-	-	-	-	-
20	ELRU2945	-	-	-	-	-	-	-	-	-	-	-
21	GAMI3343	-	-	-	-	-	-	-	-	-	-	-
22	GASO3266	-	-	-	-	-	-	-	-	-	-	-
23	JODU1309	-	-	-	-	-	-	-	-	-	-	-
24	JOFA3241	-	-	-	-	-	-	-	-	-	-	-
25	KAMU3214	-	DC									
26	LERA3235	-	-	-	-	-	-	-	-	-	-	-

ANNEX 3 – Individual Scores: Control (*continued*)

3.1 Induction Phase and Challenge Phase Individual Scores of the empty semi-occlusive patch (*continued*)

VOLUNTEERS		INDUCTION									CHALLENGE	
Ref	Vol	1	2	3	4	5	6	7	8	9	48h	72h
27	LUAB1473	-	-	-	-	-	-	-	-	-	-	-
28	LULA2873	-	-	-	-	-	-	-	-	-	-	-
29	MACA2684	-	-	-	-	-	-	-	-	-	-	-
30	MAOS2687	-	-	-	-	-	-	-	-	-	-	-
31	MAPI3257	-	-	-	-	-	-	-	-	-	-	-
32	MARO3197	-	DC									
33	MASE1804	-	-	-	-	-	-	-	-	-	-	-
34	MAZA3008	-	-	-	-	-	-	-	-	-	-	-
35	MICL2944	-	-	-	-	-	-	-	-	-	-	-
36	MOAB2550	-	-	-	-	-	-	-	-	-	-	-
37	MOSA3081	-	-	-	-	-	-	-	-	-	-	-
38	NAAN2076	-	-	-	-	-	-	-	-	-	-	-
39	NAIL2642	-	-	-	-	-	-	-	-	-	-	-
40	OUEL3268	-	-	-	-	-	-	-	-	-	-	-
41	RAMA3259	-	-	-	-	-	-	-	-	-	-	-
42	RODO1852	-	-	-	-	-	-	-	-	-	-	-
43	RORO3238	-	-	-	-	-	-	-	-	-	-	-
44	SAJA3115	-	-	-	-	-	-	-	-	-	-	-
45	TADE3031	-	-	-	-	-	-	-	-	-	-	-
46	VAAC3302	-	-	-	-	-	-	-	-	-	-	-
47	VILA2614	-	-	-	-	-	-	-	-	-	-	-
48	WACH2180	-	-	-	-	-	-	-	-	-	-	-
49	YERA3195	-	-	-	-	-	-	-	-	-	-	-
50	YERU3250	-	-	-	-	-	-	-	-	-	-	-
51	YHLE3236	-	-	-	-	-	-	-	-	-	-	-
52	YUGU3237	-	-	-	-	-	-	-	-	-	-	-
53	ZUDO3342	-	-	-	-	-	-	-	-	-	-	-

ANNEX 4 – INCI Composition

Water/Aqua/Eau, Malus Domestica Fruit Cell Culture Extract, D-Panthenol, Indian Frankincense (Boswellia Serrata) Resin Extract, rh-Polypeptide-3, Biotinoyl Tripeptide-1, Acetyl Tetrapeptide-3, Myristoyl Pentapeptide-17, Myristoyl Octapeptide-1, Glycerin (and) Sodium Metabisulfite (and) Glycine (and) Larix Europaea Wood Extract (and) Zinc Chloride (and) Camellia Sinensis Leaf Extract, Vitis Vinifera (Grape) Seed Extract, Radix Polygoni Multiflori Preparata Extract, Glycine Soja (Soybean) Extract, Saw Palmetto (Serenoa Repens) Fruit Extract, Sodium Hyaluronate, Phenoxyethanol, Nettle (Urtica Dioica) Root Extract, Palmitoyl Tripeptide-1, Tripeptide-3 (AHK), Mannitol, Copper Tripeptide-1, Prezatide Copper Acetate, Crithmum Maritimum (Sea Fennel) Extract.